Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$15.9MCash on Hand
27mo Cash Runway
Follow CMND by emailGet an email when CMND reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CMND, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Clinical trial Clearmind completed enrollment for Part C of the CMND-100 Phase I/IIa trial, a randomized, double-blind, placebo-controlled multiple-dose study assessing safety, tolerability and pharmacokinetics. Part B enrolled its first cohort of patients with moderate-to-severe AUD. Form 6-K · SEC filing · Press release
Nov 10, 2026 ·
Clearmind's Chief of Global Impact, Mary-Elizabeth Gifford, was invited to join collaborative working sessions at the Frontiers of Mental Health and Recovery Summit in Washington D.C. to discuss system readiness for psychedelic therapies. The company will share updates on CMND-100 for Alcohol Use Disorder. Form 6-K · SEC filing · Press release
Oct 27, 2026 ·
Clinical trial Completed patient recruitment for the first segment of Part B of the CMND-100 Phase I/IIa trial in patients with moderate-to-severe Alcohol Use Disorder, with two single-dose cohorts (80 mg and 160 mg) of six patients each. The trial is running at sites in the United States and Israel. Form 6-K · SEC filing · Press release
Oct 16, 2026 ·
Financing Clearmind Medicine delivered notice to CLA Investors to issue $2,000,000 in convertible promissory notes for a cash purchase price of $1,800,000, or 90% of principal. The transaction is expected to close on or before October 19, 2026. Form 6-K · SEC filing
Oct 13, 2026 ·
Charging Robotics, a 51%-owned subsidiary, launched its next-generation wireless EV-charging platform for robotaxis, autonomous fleets and automated parking, rated up to 10 kW and up to 95% efficiency under specified conditions. Form 6-K · SEC filing · Press release
Oct 7, 2026 ·
Regulatory Clearmind submitted recommendations to the FDA in response to its public hearing on potential future therapeutic use of psychedelic drugs (Docket FDA-2026-N-7542). The company urges new pathways for non-hallucinogenic neuroplastogens for Alcohol Use Disorder and calls for collaboration with the VA, DoW and HHS. Form 6-K · SEC filing · Press release
Sep 30, 2026 ·
Listing Clearmind will effect a 1-for-8 reverse share split, consolidating each eight common shares into one. Nasdaq trading on the post-split basis begins October 5, 2026, reducing outstanding shares from 4,059,227 to 507,404. Fractional shares will be rounded up. Form 6-K · SEC filing
Sep 23, 2026 ·
Clearmind announced U.S. publication of three patent applications covering combinations of LSD, ketamine and ibogaine with N-acylethanolamines such as PEA, for potential uses in depression, PTSD, pain and substance use disorders. The applications come from its collaboration with NeuroThera Labs. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1/2 · Recruiting · A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CMND holds $15.9M in cash and short-term investments and burns about $1.8M/quarter from operations,
an estimated runway of 27 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:0 · Low
Cash runway 27 months
Shelf registration (F-3, Apr 2026) +10
Raised after last reported balance sheet (Dec 2025) -10
Share count 158,076 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CMND picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CMND and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.